A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 617 participants.

Also called NCT05079919

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 617 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05079919
  • EudraCT 2021-002192-19
  • EU CT 2024-510696-38-00
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Australia, Bulgaria, Canada, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Portugal, Slovakia, South Africa, Spain, Sweden, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05079919. Randomized; triple masking; primary purpose treatment. Start 2021-10-25 (actual); primary completion 2024-10-22 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia
Condition
Severe Hypertriglyceridemia
Intervention (Drug)
Olezarsen
Intervention (Drug)
Placebo
Lead sponsor
Ionis Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05079919
Content hash
59cbdf3bea98d1ecb27d9b30ef0f8dca47af8bc559e552d7680edd1af180d207